The US FTC challenges the merger between a pharmaceutical company and a cancer detection test manufacturer (Grail / Illumina)

FTC Challenges Illumina’s Proposed Acquisition of Cancer Detection Test Maker Grail* Agency alleges vertical merger would harm competition in the U.S. market for life-saving Multi-Cancer Early Detection tests The Federal Trade Commission has filed an administrative complaint (a public version of which will be available and linked to this news release as soon as possible) and authorized a federal court lawsuit to block Illumina’s $7.1 billion proposed

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

US Federal Trade Commission, The US FTC challenges the merger between a pharmaceutical company and a cancer detection test manufacturer (Grail / Illumina), 30 March 2021, e-Competitions April 2021 - II, Art. N° 99896

Visites 239

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues